Biotech | April 29, 2022
Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
The plant is expected to start commercial operations from Q4FY24
When a critical patient is en-route to the hospital and every second makes a difference, the 5G Connected ambulance acts as an extension of the emergency room
This facility will design & develop instruments, perform product reliability performance testing and verification
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Tembo and UFlex-Asepto have co-developed 100% renewable and recyclable paper straw solution that will be food grade, moisture-resistant and made from sustainably sourced papers
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Subscribe To Our Newsletter & Stay Updated
